ストックスクリーナーアプリを入手
0.9166
11.01%
-0.1134
アフターアワーズ：
.92
0.0034
+0.37%
Lyell Immunopharma Inc (LYEL) 最新ニュース
Lyell Immunopharma (LYEL) Upgraded to Buy: Here's What You Should Know - MSN
HC Wainwright Reiterates "Neutral" Rating for Lyell Immunopharma (NASDAQ:LYEL) - MarketBeat
The Analyst Verdict: Lyell Immunopharma In The Eyes Of 4 Experts - Benzinga
Lyell Immunopharma: Q3 Earnings Snapshot - AOL
Lyell Immunopharma Reports Q3 2024 Financial Results - TipRanks
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024 - GlobeNewswire
Lyell Announces Presentation of Initial Clinical Data from - GlobeNewswire
Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting - GlobeNewswire
Lyell's Novel CAR T-Cell Therapy Data to Be Unveiled at ASH 2024 Following FDA Fast Track Status | LYEL Stock News - StockTitan
Vanguard Group Inc's Strategic Reduction in Lyell Immunopharma I - GuruFocus.com
Lyell shares down as BofA double downgrades to Sell - MSN
Lyell Immunopharma (NASDAQ:LYEL) Downgraded to “Underperform” Rating by Bank of America - Defense World
Lyell Immunopharma Completes Acquisition of ImmPACT Bio South San Francisco, Calif., Oct. 31, 2024 – Lyell Immunopharma, Inc. (NASDAQ: LYEL), a clinical-stage T-cell reprogramming company focusing on next-generation CAR T-cell therapies for solid - Defense World
Lyell Immunopharma Completes Acquisition of ImmPACT Bio - The Manila Times
Lyell Immunopharma acquires ImmPACT Bio to boost CAR T-cell therapy - Investing.com India
B of A Securities Downgrades Lyell Immunopharma (LYEL) - MSN
Lyell Immunopharma’s (LYEL) “Neutral” Rating Reiterated at HC Wainwright - Defense World
Lyell shares down as BofA double downgrades to Sell By Investing.com - Investing.com Australia
Lyell Immunopharma Downgraded, Analyst Flags Concerns Over Acquisition Strategy - Benzinga
Lyell cut to underperform by BofA, pipeline reorganization cited - MSN
Lyell Immunopharma (NASDAQ:LYEL) Lowered to Underperform Rating by Bank of America - MarketBeat
HC Wainwright Reiterates Neutral Rating for Lyell Immunopharma (NASDAQ:LYEL) - MarketBeat
Lyell Immunopharma’s Acquistion of ImmPACT Bio USA - Global Legal Chronicle
Lyell Will Seek To Improve On Existing CAR-Ts Via Merger With ImmPACT - Citeline News & Insights
Lyell Immunopharma stock hits 52-week low at $1.05 By Investing.com - Investing.com Australia
Lyell goes all in on CAR-T therapies, buys ImmPACT Bio and trims pipeline - Pharmaceutical Technology
Lyell Immunopharma stock hits 52-week low at $1.05 - Investing.com
Lyell Immunopharma: Oversold And Poised For A Turning Point To Growth (NASDAQ:LYEL) - Seeking Alpha
Lyell boosts pipeline with ImmPACT acquisition - Investing.com India
Lyell, in search of a turnaround, to buy cell therapy startup ImmPact - BioPharma Dive
Lyell Immunopharma to Buy ImmPact; Refocuses Pipeline on T-Cell Cancer Treatments - MarketWatch
Lyell Immunopharma to acquire ImmPACT Bio (NASDAQ:LYEL) - Seeking Alpha
Lyell boosts pipeline with ImmPACT acquisition By Investing.com - Investing.com South Africa
Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes - GlobeNewswire
0.93%
3.55%
大文字化:
|
ボリューム (24 時間):